{
  "url": "https://www.law.cornell.edu/regulations/new-york/10-NYCRR-1004.2",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 10 ยง 1004.2 - Practitioner issuance of certification",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 10 ยง 1004.2 - Practitioner issuance of certification\n\nState Regulations\n(a) Requirements for Patient\n\nCertification. A practitioner who is registered pursuant to 1004.1 of\nthis part may issue a certification for the use of an approved medical\nmarihuana product by a qualifying patient subject to completion of subdivision\n(e) of this section. Such certification shall contain: (1)\nthe practitioner's name, business\naddress, telephone number and email address; (2)\nthe practitioner's license number as\nissued by the New York State Department of Education; (3)\nthe practitioner's drug enforcement\nadministration registration number; (4)\na statement that the practitioner is\nlicensed and in good standing in New York State and possesses an active\nregistration with the drug enforcement administration; (5)\na statement that the practitioner is\nregistered with the department to issue the certification; (6)\na statement that the practitioner is\ncaring for the patient in relation to the patient's serious\ncondition; (7)\nthe patient's name, date of birth, address, telephone number and email address if\navailable; (8)\nthe patient's\ndiagnosis, limited solely to the specific severe debilitating or\nlife-threatening condition(s) listed below; (i) cancer; (ii)\npositive status for human\nimmunodeficiency virus or acquired immune deficiency syndrome, provided that\nthe practitioner has obtained from the patient consent for disclosure of this\ninformation that meets the requirements set forth in sections\n2780\nand\n2782\nof the\n\nPublic Health Law; (iii)\namyotrophic lateral sclerosis; (iv)\n\nParkinson's disease; (v) multiple\nsclerosis; (vi)\ndamage to the\nnervous tissue of the spinal cord with objective neurological indication of\nintractable spasticity; (vii)\nepilepsy; (viii)\ninflammatory bowel\ndisease; (ix)\nneuropathies; (x) Huntington's\ndisease; (xi)\nany severe\ndebilitating pain that the practitioner determines degrades health and\nfunctional capability; where the patient has contraindications, has experienced\nintolerable side effects, or has experienced failure of one or more previously\ntried therapeutic options; and where there is documented medical evidence of\nsuch pain having lasted three months or more beyond onset, or the practitioner\nreasonably anticipates such pain to last three months or more beyond\nonset; (xii)\npost-traumatic\nstress disorder; (xiii)\npain that degrades health and functional capability where the use of medical\nmarihuana is an alternative to opioid use, provided that the precise underlying\ncondition is expressly stated on the patient's certification; or\n(xiv)\nsubstance use disorder; or\n(xv)\nany other condition added by the\ncommissioner. (9)\n\nThe\ncondition or symptom that is clinically associated with, or is a complication\nof the severe debilitating or life-threatening condition listed in paragraph\n(8) of this subdivision. Clinically associated conditions, symptoms or\ncomplications, as defined in subdivision seven of section\nthirty-three hundred\nsixty\nof the public health law are limited solely to: (i) Cachexia or wasting syndrome; (ii)\nsevere or chronic pain resulting in\nsubstantial limitation of function; (iii)\nsevere nausea; (iv)\nseizures; (v) severe or persistent muscle\nspasms; (vi)\npost-traumatic stress\ndisorder; (vii)\nopioid use\ndisorder; or\n(viii)\nsuch other\nconditions, symptoms or complications as added by the\ncommissioner. (10)\na\nstatement that by training or experience, the practitioner is qualified to\ntreat the serious condition, which encompasses the severe debilitating or\nlife-threatening condition listed pursuant to paragraph (8) of this subdivision\nand the clinically associated condition, symptom or complication listed\npursuant to paragraph (9) of this subdivision; (i) for purposes of this subdivision, a\npractitioner must hold a federal Drug Addiction Treatment Act of 2000 (DATA\n2000) waiver to be qualified to treat patients with substance use disorder or\nopioid use disorder. (11)\na statement that in the practitioner's professional opinion and review of past\ntreatments, the patient is likely to receive therapeutic or palliative benefit\nfrom the primary or adjunctive treatment with medical marihuana for the serious\ncondition; (12)\nany recommendations\nor limitations the practitioner makes to the certified patient and/or the\npatient's designated caregiver concerning: (i) the authorized brand, authorized form, administration method, dosage and any limitations in the use of the approved\nmedical marihuana product; and\n(ii)\nthe total amount of usable approved medical marihuana product that may be\ndispensed to the patient, in measurable controlled doses, which shall not\nexceed a 30 day supply, if used as directed; (13)\na statement that the practitioner has\nexplained the potential risks and benefits of the use of medical marihuana to\nthe qualifying patient and has documented in the patient's medical record that\nsuch explanation has been provided to the patient; (14)\nto the extent that a practitioner is\nseeking to authorize the use of an approved medical marihuana product by a\npatient who is under the age of 18 or a person who is otherwise incapable of\nconsenting to medical treatment, the practitioner shall explain the potential\nrisks and benefits of medical marihuana to the patient's parent or legal\nguardian, and if appropriate, to the minor patient. The practitioner shall\ndocument in the patient's medical record that such explanation has been\nprovided as required herein; and\n(15)\na statement that the patient, or the\npatient's parent or legal guardian if applicable, has provided informed\nconsent; and. (16)\nto the extent\nthat a practitioner seeks to authorize the use of an approved medical marihuana\nproduct by a patient who temporarily resides in New York State for the purpose\nof receiving care and treatment from the practitioner, the practitioner shall\nso state on the patient's certification. (b) Expiration of certification. (1)\n\nThe certification shall state the date\nupon which the certification shall expire, which shall be no longer than one\nyear after the date it was issued, unless the patient is terminally\nill. (2)\n\nIf the practitioner issues\na certification to a patient who is terminally ill, the certification shall not\nexpire until the patient's death or the practitioner revokes the\ncertification. (3)\n\nIf the\npractitioner issues a certification to a patient who is not a resident of New\n\nYork but is receiving care and treatment in this state, the certification shall\nbe valid for a period of time which is no longer than the applicant is\nreasonably anticipated to be residing in New York State for the purposes of\ncare and treatment, but in no event shall it be valid for more than one year\nafter the date it was issued. (c) Submission of certification to the\ndepartment. Practitioners shall utilize a form, which may be in an\nelectronic format, developed by the department for the certification required\nin subdivision (a) of this section. The practitioner shall submit to the\ndepartment, the information required by subdivision (a) of this section, in a\nmanner determined by the department, including by electronic transmission\nthrough a secure website. In the instance that a practitioner submits this\ninformation to the department electronically, the practitioner shall retain, for a period of five years, a printed copy of the electronic certification that\nshall contain the information required in subdivision (a) of this\nsection. (d) Medical\nrecord retention. The practitioner shall date and place his or her handwritten\nsignature upon the printed certification, and provide the printed certification\nto the patient. The practitioner shall also maintain a copy of the signed\ncertification in the patient's medical record. (e) Consultation of Prescription\n\nMonitoring Program Registry. Prior to issuing, modifying or renewing a\ncertification, the practitioner shall consult the prescription monitoring\nprogram registry pursuant to section\n3343-a\nof\nthe Public Health Law for the purpose of reviewing a patient's controlled\nsubstance history. Practitioners may authorize a designee to consult the\nprescription monitoring program registry on their behalf, provided that such\ndesignation is in accordance with section\n3343-a\nof\nthe Public Health Law. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 10\nยง\n1004.2\n\nAdopted, New\n\nYork State Register April 15, 2015/Volume XXXVII, Issue 15, eff. 4/15/2015\n\nAmended\n\nNew\n\nYork State Register March 22, 2017/Volume XXXIX, Issue 12, eff. 3/22/2017\n\nAmended\n\nNew\n\nYork State Register December 27, 2017 /Volume XXXIX, Issue 52, eff. 12/27/2017\n\nAmended\n\nNew\n\nYork State Register July 3, 2019/Volume XLI, Issue 27, eff. 7/3/2019\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 49666
}